CARsgen Therapeutics raises HK$462M via share placing to fuel global R&D
What's the deal? CARsgen Therapeutics, a Hong Kong-listed biotech company, has completed a HK$462 million share placing and subscription. The funds will be directed toward global drug development and expanding its research and development operations.
Why now? The capital raise comes as CARsgen pushes to advance its pipeline of cell therapy candidates through clinical development and toward commercialisation. Biotech firms often tap equity markets when they need runway to fund late-stage trials and global expansion efforts.
The signal: CARsgen Therapeutics, classified as a late-growth stage company on Dealroom, is leaning on public equity markets to bankroll its next phase — a pattern increasingly common among clinical-stage biotechs that have yet to generate significant commercial revenue. The raise underscores how capital-intensive the path from promising CAR-T pipeline to global commercialisation remains, even for companies that have already cleared the IPO hurdle.
Read more: minichart.com.sg
